Niraparib news

All news on Niraparib (also known as Zejula): plants, production capacities, investments and involved companies.

16 October 2025
Johnson & Johnson's AKEEGA® Gets FDA Priority Review for BRCA-Mutated Prostate Cancer
FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.

Who will be producing Niraparib in the future?

Find out with chemXplore Analytics